Bergen Op Zoom

Physical restraints are still frequently used in about 20-25% of adult ICU patients in the Netherlands who are agitated or expected to become agitated, despite their harmful short- and long-term effects. This research evaluates the effectiveness of a person-centered multicomponent intervention (MCI) program that combines non-drug approaches with goal-directed light sedation using dexmedetomidine. The study compares this new approach with the traditional standard care that includes physical restraints, aiming to improve patient safety and outcomes during ICU stays. The intervention group will receive the MCI program, which involves non-pharmacological strategies and light sedation with dexmedetomidine as needed to manage agitation. This is compared against the current standard care involving physical restraints. The study focuses on adult ICU patients expected to stay longer than 24 hours and who show or are expected to show agitation within the first 14 days of ICU admission. The trial monitors short- and long-term outcomes as well as healthcare costs. Participants' involvement includes monitoring ICU-free days over 28 days as a primary outcome. Researchers will assess agitation levels, sedation needs, and the use of physical restraints. Safety and long-term effects will be tracked, with consent required for extended follow-up in related studies. The study excludes patients with certain neurological conditions, substance intoxication, or other risks, and requires participants or their relatives to understand Dutch for follow-up communication.

Researchers are evaluating the (cost)effectiveness of the Occupational Therapy at Home E-Rehabilitation (OTHER) intervention compared to usual occupational therapy care in older adults recovering from stroke. The study focuses on community-dwelling persons aged 60 and older in geriatric rehabilitation, aiming to improve self-perceived performance in daily activities, satisfaction with performance, physical activity, and self-management over 26 weeks. It also explores participant and therapist experiences with the intervention and investigates factors affecting its delivery and benefits. The OTHER intervention involves occupational therapists using activity monitoring, coaching, and videoconferencing to support the transition from clinical care to home. Participants receive this treatment over a 24-week period, with assessments at weeks 4, 13, and 26. The study compares this approach to standard occupational therapy to determine differences in outcomes such as daily functioning and quality-adjusted life years. Participants will be involved in regular evaluations including the Canadian Occupational Performance measure at three time points to track changes in daily activity performance. Researchers will monitor treatment fidelity, barriers, facilitators, and cost-effectiveness. The study includes qualitative assessments to understand experiences of stroke survivors and therapists and their reflections on the intervention. Total participation lasts for about 26 weeks with ongoing monitoring.

This research focuses on participants with Hidradenitis Suppurativa (HS) who have previously taken part in specific Incyte-sponsored clinical trials of povorcitinib. The study is a Phase 3b rollover trial designed to continue monitoring these individuals to gather further information on the treatment. It aims to evaluate the safety of povorcitinib over an extended period, including the proportion of participants experiencing treatment-emergent adverse events for up to about three years. Participants will continue taking the study drug povorcitinib orally as specified by the study protocol. This rollover study includes individuals who completed the treatment period in the parent studies without safety or tolerability issues and who showed clinical benefit from povorcitinib. During this study, participants will follow the protocol-defined dosing and procedures while avoiding pregnancy or fathering children as required. Throughout the study, participants will attend scheduled visits and assessments to monitor their health and treatment effects. Researchers will track adverse events and adherence to the treatment plan. The study involves ongoing evaluation for up to approximately three years to ensure safety and collect important long-term data on povorcitinib use in this group of patients with HS.